Technical Analysis for MGX - Metagenomi, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.28% | |
| Wide Bands | Range Expansion | 0.28% | |
| Gapped Up | Strength | 0.28% | |
| Wide Bands | Range Expansion | -13.09% | |
| Oversold Stochastic | Weakness | -13.09% | |
| Wide Bands | Range Expansion | -6.51% | |
| Oversold Stochastic | Weakness | -6.51% | |
| Wide Bands | Range Expansion | 4.45% | |
| Oversold Stochastic | Weakness | 4.45% |
| Alert | Time |
|---|---|
| Possible NR7 | about 5 hours ago |
| Possible Inside Day | about 5 hours ago |
| Rose Above 10 DMA | about 9 hours ago |
| Up 5% | about 9 hours ago |
| 10 DMA Resistance | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: Unknown
Metagenomi, Inc. Description
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Molecular Biology Genetic Engineering CRISPR Genome Editing Biological Engineering Gene Editing Human Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.74 |
| 52 Week Low | 6.5 |
| Average Volume | 124,747 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 10.11 |
| 20-Day Moving Average | 8.23 |
| 10-Day Moving Average | 7.15 |
| Average True Range | 0.77 |
| RSI (14) | 35.90 |
| ADX | 35.88 |
| +DI | 15.26 |
| -DI | 25.55 |
| Chandelier Exit (Long, 3 ATRs) | 8.61 |
| Chandelier Exit (Short, 3 ATRs) | 8.82 |
| Upper Bollinger Bands | 10.70 |
| Lower Bollinger Band | 5.76 |
| Percent B (%b) | 0.26 |
| BandWidth | 60.07 |
| MACD Line | -0.93 |
| MACD Signal Line | -0.95 |
| MACD Histogram | 0.0166 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.75 | ||||
| Resistance 3 (R3) | 7.81 | 7.64 | 7.63 | ||
| Resistance 2 (R2) | 7.64 | 7.46 | 7.61 | 7.59 | |
| Resistance 1 (R1) | 7.34 | 7.35 | 7.49 | 7.28 | 7.55 |
| Pivot Point | 7.17 | 7.17 | 7.25 | 7.14 | 7.17 |
| Support 1 (S1) | 6.87 | 6.99 | 7.02 | 6.81 | 6.53 |
| Support 2 (S2) | 6.70 | 6.88 | 6.67 | 6.49 | |
| Support 3 (S3) | 6.40 | 6.70 | 6.45 | ||
| Support 4 (S4) | 6.34 |
